No randomised evidence defines the optimal treatment for localised prostate cancer.
Radiotherapy can be curative for localised disease.
Trial quality assurance is necessary with increasing radiotherapy dose and complexity.
The ProtecT trial reports on active monitoring, radiotherapy and surgery in 2016.